is part of the Informa Markets Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Almost six months since the earliest detected cases of COVID-19 in Wuhan Province China, the pandemic has since spread rapidly in breadth and depth. The increased strain the disease has placed on healthcare facilities is being realised in countries with the highest number of cases. This insight is intended to provide an update on its impact on the X-ray market.
COVID-19 has diverted stimulus funds to diagnostic X-ray systems to help facilitate much needed diagnostic imaging facilities, resulting in a higher than anticipated uplift in the radiography market in Q1 and Q2 of 2020 than predicted previously pre-COVID-19. Mobile digital radiography (DR) systems are at the forefront in providing an initial screening for pneumonia, a secondary and more progressive stage of COVID-19 in severe cases.
Imaging is not routinely designated in asymptomatic individuals with mild COVID-19 symptoms unless they are at risk for disease progression. Mobile DR systems are used heavily to track progression of pneumonia due to the capabilities of bed side imaging enabling use in emergency rooms, A&E facilities and in the ICU. Mobile DR imaging has benefits of offering quicker, and less costly imaging services than other modalities.
Read More: insights.omnia-health.com